Total Payments
$278,951
2024 Payments
$111,326
Companies
68
Transactions
1,479
Medicare Patients
2,520
Medicare Billing
$400,946
Payment Breakdown by Category
Other$186,991 (67.0%)
Consulting$43,478 (15.6%)
Travel$27,085 (9.7%)
Food & Beverage$21,007 (7.5%)
Education$390.55 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $186,991 | 114 | 67.0% |
| Consulting Fee | $43,478 | 22 | 15.6% |
| Travel and Lodging | $27,085 | 94 | 9.7% |
| Food and Beverage | $21,007 | 1,239 | 7.5% |
| Education | $390.55 | 10 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | $101,971 | 163 | $0 (2024) |
| ARGENX US, INC. | $75,002 | 86 | $0 (2024) |
| UCB, Inc. | $53,845 | 117 | $0 (2024) |
| ABBVIE INC. | $26,878 | 151 | $0 (2024) |
| Supernus Pharmaceuticals, Inc. | $4,504 | 152 | $0 (2021) |
| Amgen Inc. | $2,877 | 46 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $2,481 | 15 | $0 (2024) |
| Allergan, Inc. | $1,395 | 70 | $0 (2022) |
| Teva Pharmaceuticals USA, Inc. | $949.68 | 58 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $883.24 | 72 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $111,326 | 280 | UCB, Inc. ($41,298) |
| 2023 | $87,171 | 188 | ARGENX US, INC. ($39,378) |
| 2022 | $55,228 | 182 | Alexion Pharmaceuticals, Inc. ($36,927) |
| 2021 | $11,004 | 218 | AbbVie Inc. ($7,365) |
| 2020 | $2,098 | 126 | Alexion Pharmaceuticals, Inc. ($459.37) |
| 2019 | $6,542 | 255 | Alexion Pharmaceuticals, Inc. ($3,987) |
| 2018 | $5,029 | 197 | Supernus Pharmaceuticals, Inc. ($3,387) |
| 2017 | $553.16 | 33 | Teva Pharmaceuticals USA, Inc. ($175.10) |
All Payment Transactions
1,479 individual payment records from CMS Open Payments — Page 1 of 60
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $23.35 | General |
| Category: Neuropsychiatry | ||||||
| 12/19/2024 | ABBVIE INC. | QULIPTA (Drug), BOTOX | Food and Beverage | In-kind items and services | $20.32 | General |
| Category: NEUROSCIENCE | ||||||
| 12/18/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $21.07 | General |
| Category: Neurology | ||||||
| 12/17/2024 | UCB, Inc. | Zilbrysq (Drug) | Food and Beverage | In-kind items and services | $12.38 | General |
| Category: Neurology | ||||||
| 12/12/2024 | UCB, Inc. | Zilbrysq (Drug) | Food and Beverage | In-kind items and services | $38.10 | General |
| Category: Neurology | ||||||
| 12/11/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $23.36 | General |
| Category: Neurology | ||||||
| 12/10/2024 | UCB, Inc. | Zilbrysq (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,050.00 | General |
| Category: Neurology | ||||||
| 12/05/2024 | SK Life Science, Inc. | — | Food and Beverage | In-kind items and services | $19.56 | General |
| 12/04/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $25.11 | General |
| Category: Rare Disease | ||||||
| 12/03/2024 | UCB, Inc. | Rystiggo (Drug) | Consulting Fee | Cash or cash equivalent | $840.00 | General |
| Category: Neurology | ||||||
| 12/03/2024 | UCB, Inc. | Zilbrysq (Drug) | Food and Beverage | In-kind items and services | $12.65 | General |
| Category: Neurology | ||||||
| 11/27/2024 | PFIZER INC. | PANZYGA (Biological) | Food and Beverage | In-kind items and services | $13.84 | General |
| Category: IMMUNOLOGY;INFLAMMATION | ||||||
| 11/26/2024 | Amgen Inc. | UPLIZNA (Biological) | Consulting Fee | Cash or cash equivalent | $2,200.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/26/2024 | UCB, Inc. | Zilbrysq (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,050.00 | General |
| Category: Neurology | ||||||
| 11/25/2024 | UCB, Inc. | Zilbrysq (Drug) | Food and Beverage | In-kind items and services | $12.56 | General |
| Category: Neurology | ||||||
| 11/25/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $10.99 | General |
| 11/22/2024 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $27.29 | General |
| Category: Neurology | ||||||
| 11/21/2024 | Lilly USA, LLC | EMGALITY (Drug), AMYVID, REYVOW | Food and Beverage | In-kind items and services | $19.18 | General |
| Category: Neuroscience | ||||||
| 11/21/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $4.60 | General |
| Category: Central Nervous System | ||||||
| 11/19/2024 | ABBVIE INC. | UBRELVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,000.00 | General |
| Category: NEUROSCIENCE | ||||||
| 11/18/2024 | UCB, Inc. | Zilbrysq (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,500.00 | General |
| Category: Neurology | ||||||
| 11/18/2024 | UCB, Inc. | Rystiggo (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,050.00 | General |
| Category: Neurology | ||||||
| 11/18/2024 | UCB, Inc. | Zilbrysq (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,050.00 | General |
| Category: Neurology | ||||||
| 11/18/2024 | UCB, Inc. | Rystiggo (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,050.00 | General |
| Category: Neurology | ||||||
| 11/15/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: Neurology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 548 | 593 | $200,801 | $70,549 |
| 2022 | 9 | 594 | 6,411 | $246,216 | $98,641 |
| 2021 | 11 | 650 | 8,021 | $283,513 | $116,224 |
| 2020 | 12 | 728 | 9,603 | $309,675 | $115,532 |
Total Patients
2,520
Total Services
24,628
Medicare Billing
$400,946
Procedure Codes
60
All Medicare Procedures & Services
60 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 99 | 99 | $36,167 | $15,227 | 42.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 90 | 91 | $47,739 | $12,230 | 25.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 84 | 95 | $23,365 | $11,493 | 49.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 46 | 65 | $11,931 | $5,996 | 50.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 43 | 43 | $19,112 | $5,422 | 28.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 40 | 50 | $9,357 | $4,467 | 47.7% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2023 | 12 | 13 | $7,920 | $3,482 | 44.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 33 | 33 | $13,950 | $3,386 | 24.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 24 | 25 | $7,318 | $2,547 | 34.8% |
| 95957 | Measurement of brain wave activity (eeg), digital analysis | Office | 2023 | 11 | 12 | $9,408 | $2,509 | 26.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 15 | 15 | $6,405 | $1,485 | 23.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 25 | 25 | $4,574 | $1,263 | 27.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 14 | 14 | $2,632 | $726.18 | 27.6% |
| 96138 | Administration of psychological or neuropsychological test by technician, first 30 minutes | Office | 2023 | 12 | 13 | $923.00 | $315.72 | 34.2% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 12 | 5,775 | $45,280 | $25,787 | 56.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 120 | 122 | $61,013 | $18,042 | 29.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 90 | 90 | $33,000 | $14,129 | 42.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 72 | 84 | $20,734 | $10,714 | 51.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 73 | 98 | $17,142 | $7,712 | 45.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 48 | 48 | $20,996 | $5,970 | 28.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 52 | 60 | $11,457 | $5,028 | 43.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 30 | 30 | $12,180 | $3,013 | 24.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 21 | 23 | $6,460 | $2,496 | 38.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 38 | 43 | $7,236 | $2,285 | 31.6% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2022 | 11 | 11 | $5,560 | $2,220 | 39.9% |
About Dr. Jon Durrani, DO
Dr. Jon Durrani, DO is a Neurology healthcare provider based in Centerville, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/27/2011. The National Provider Identifier (NPI) number assigned to this provider is 1932495157.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jon Durrani, DO has received a total of $278,951 in payments from pharmaceutical and medical device companies, with $111,326 received in 2024. These payments were reported across 1,479 transactions from 68 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($186,991).
As a Medicare-enrolled provider, Durrani has provided services to 2,520 Medicare beneficiaries, totaling 24,628 services with total Medicare billing of $400,946. Data is available for 4 years (2020–2023), covering 60 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Centerville, OH
- Active Since 06/27/2011
- Last Updated 07/11/2024
- Taxonomy Code 2084N0400X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1932495157
Products in Payments
- VYVGART (Drug) $66,686
- ULTOMIRIS (Biological) $65,563
- Zilbrysq (Drug) $21,758
- Rystiggo (Drug) $21,295
- UBRELVY (Drug) $18,231
- QULIPTA (Drug) $9,067
- SOLIRIS (Biological) $7,041
- TROKENDI XR (Drug) $4,482
- SOLIRIS (Drug) $4,096
- Zilbrysq (Biological) $3,150
- VYVGART HYTRULO (Drug) $2,773
- XYWAV (Drug) $2,356
- UPLIZNA (Biological) $2,200
- Soliris (Drug) $1,050
- BOTOX (Biological) $697.27
- Aimovig (Biological) $604.98
- EMGALITY (Drug) $485.62
- NURTEC ODT (Drug) $480.67
- KESIMPTA (Drug) $419.69
- APTIOM (Drug) $376.87
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Centerville
Dr. Kenneth Pugar, D.o, D.O
Neurology — Payments: $732,730
Neurology $732,730
Dr. Timothy Schoonover, D.o, D.O
Neurology — Payments: $432,352
Neurology $432,352
Megan Mackenzie, D.o, D.O
Neurology — Payments: $66,466
Neurology $66,466
Mrs. Sarah Dooley, P.a, P.A
Neurology — Payments: $12,580
Neurology $12,580
Dr. Nicole Alexander, D.o, D.O
Neurology — Payments: $11,068
Neurology $11,068
Dr. Petre Udrea, M.d, M.D
Neurology — Payments: $5,481
Neurology $5,481